摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-hydroxy-4-[2-[3-(2-hydroxyphenyl)prop-2-enoylamino]ethoxy]benzamide

中文名称
——
中文别名
——
英文名称
N-hydroxy-4-[2-[3-(2-hydroxyphenyl)prop-2-enoylamino]ethoxy]benzamide
英文别名
——
N-hydroxy-4-[2-[3-(2-hydroxyphenyl)prop-2-enoylamino]ethoxy]benzamide化学式
CAS
——
化学式
C18H18N2O5
mdl
——
分子量
342.3
InChiKey
BXPAJELCROVQMS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    25
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    108
  • 氢给体数:
    4
  • 氢受体数:
    5

文献信息

  • Novel hydroxamates as therapeutic agents
    申请人:Verner J. Erik
    公开号:US20050187261A1
    公开(公告)日:2005-08-25
    The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    本发明涉及某些羟酸酰胺衍生物,其在治疗丙型肝炎方面具有用途。这些化合物也是组蛋白去乙酰化酶的抑制剂,因此在治疗与组蛋白去乙酰化酶活性相关的疾病方面也具有用途。此外,还公开了制备这些化合物的制药组合物和方法。
  • NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
    申请人:Verner Erik J.
    公开号:US20090220454A1
    公开(公告)日:2009-09-03
    The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    本发明涉及某些羟肟酸衍生物,可用于治疗丙型肝炎。这些化合物也是组蛋白去乙酰化酶的抑制剂,因此可用于治疗与组蛋白去乙酰化酶活性相关的疾病。同时,还公开了制备这些化合物的药物组合物和过程。
  • Method of Monitoring Anti-Tumor Activity of an Hdac Inhibitor
    申请人:Bass Kathryn E.
    公开号:US20080248506A1
    公开(公告)日:2008-10-09
    The present invention relates to the method of determining the anti-tumor activity of a histone deacetylase inhibitor by measuring the phosphorylation of the histone variant H2AX or the level of cytokeratin-18 fragment aa 387-397.
    本发明涉及一种通过测量组蛋白去乙酰化酶抑制剂引起的组蛋白变异体H2AX的磷酸化或细胞角蛋白18片段aa 387-397水平来确定抗肿瘤活性的方法。
  • HYDROXAMATES AS THERAPEUTIC AGENTS
    申请人:Pharmacyclics, Inc.
    公开号:EP1611088B1
    公开(公告)日:2009-06-17
  • US7276612B2
    申请人:——
    公开号:US7276612B2
    公开(公告)日:2007-10-02
查看更多